An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
Status:
Enrolling by invitation
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Stoke Therapeutics is evaluating the long-term safety & tolerability of repeated doses of
STK-001 in patients with Dravet syndrome who previously participated in studies of STK-001.
Change in seizure frequency and overall clinical status, and quality of life will be measured
as secondary endpoints in this open-label study.